Share Incentive Plan - The company granted a total of 150,000 restricted shares to Dr. Liang Dongke under the share incentive plan [3]. - The purchase price for the granted shares was RMB 12.0, while the market price on the grant date was HKD 28.6 [4]. - The company has a lock-up period of 60 months starting from May 13, 2022, for the granted shares [4]. - The incentive plan includes a clawback mechanism for cases of misconduct or breach of duty by the incentive recipients [6]. - If the incentive recipient leaves the company before the lock-up period ends, the shares will be repurchased at the purchase price [8]. - The performance indicators for the incentive plan are based on net profit growth rates from 2019 as a baseline [4]. - The company stated that the number of shares available for future grants under the share incentive plan is zero following the completion of the grant [19]. - If an incentive object loses labor ability due to work-related injury, shares will be repurchased at the purchase price plus bank interest if the lock-up period is not completed [13]. - In the event of the death of an incentive object due to work-related duties, shares that have been realized will not be processed, while unrealized shares will be repurchased [14]. - If an incentive object no longer qualifies due to violations, shares will not be processed if the lock-up period is completed; otherwise, unrealized shares will be repurchased [18]. - The company will repurchase shares of an incentive object if the company loses control over the subsidiary where the incentive object works, depending on the lock-up period [17]. - The company will terminate the grant of domestic shares that have not been completed due to installment issuance [13][14][17][18]. - The company emphasized that the repurchase amount will be received by the designated heirs or legal heirs of the deceased incentive object [15]. - The company will not provide financial assistance arrangements for incentive objects [19]. Performance Targets and Strategies - The performance target for the 2023 fiscal year requires a net profit growth rate of no less than 60% compared to 2019 [4]. - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year [2]. - The company aims to enhance its competitive position through strategic acquisitions and partnerships [2]. - The incentive plan is designed to align the interests of the management with the long-term goals of the company [2]. Governance and Compliance - The company clarified that the previous announcement regarding exceeding Dr. Liang's personal limit violated Listing Rule 17.11, which requires compliance with the terms of the share plan [21]. - The board of directors consists of various executive and non-executive members, including Dr. Liang Dongke and Mr. Lin Sen [22].
康德莱医械(01501) - 2024 - 年度业绩